Inhibition of HIV-1 replication by a peptide dimerization inhibitor of HIV-1 protease

Antiviral Research

Volumn 72, Issue 2, 2006, Pages 89-99

  Davis, David A ^a   Brown, Cara A ^a   Singer, Kathleen E ^a   Wang, Victoria ^a   Kaufman, Joshua ^b   Stahl, Stephen J ^b   Wingfield, Paul ^b   Maeda, Kenji ^a   Harada, Shigeyoshi ^a   Yoshimura, Kazuhisa ^a   Kosalaraksa, Pope ^a   Mitsuya, Hiroaki ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Dimer; HIV 1; Inhibitor; Peptide; Polyprotein; Protease

Indexed keywords

AMPRENAVIR; INDINAVIR; LOPINAVIR; PROTEINASE; PROTEINASE INHIBITOR; PROTEINASE INHIBITOR P27; RITONAVIR; SAQUINAVIR; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; CYTOTOXICITY; DIMERIZATION; DRUG RESISTANCE; GENE DISRUPTION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PROCESSING; VIRUS INHIBITION; VIRUS REPLICATION;

CELL LINE; DIMERIZATION; FUSION PROTEINS, GAG-POL; GENE PRODUCTS, TAT; HIV CORE PROTEIN P24; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; PEPTIDES; PROTEIN PROCESSING, POST-TRANSLATIONAL; T-LYMPHOCYTES; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33748457900     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.03.015     Document Type: Article

References (57)

1. Babé L.M., Rose J., and Craik C.S. Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci. 1 (1992) 1244-1253
2. Babé L.M., Rose J., and Craik C.S. Trans-dominant inhibitory human immunodeficiency virus type 1 protease monomers prevent protease activation and virion maturation. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 10069-10073
3. Bonny C., Oberson A., Negri S., Sauser C., and Schorderet D.F. Cell-permeable peptide inhibitors of JNK: novel blockers of beta-cell death. Diabetes 50 (2001) 77-82
4. Brooks H., Lebleu B., and Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv. Drug Deliv. Rev. 57 (2005) 559-577
5. Cabana M., Clotet B., and Martinez M.A. Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors. J. Med. Virol. 59 (1999) 480-490
6. Ceccherini-Silberstein F., Erba F., Gago F., Bertoli A., Forbici F., Bellocchi M.C., Gori C., D'Arrigo R., Marcon L., Balotta C., Antinori A., Monforte A.D., and Perno C.F. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS 18 (2004) F11-F19
7. Chen L., Wright L.R., Chen C.H., Oliver S.F., Wender P.A., and Mochly-Rosen D. Molecular transporters for peptides: delivery of a cardioprotective epsilonPKC agonist peptide into cells and intact ischemic heart using a transport system, R(7). Chem. Biol. 8 (2001) 1123-1129
8. Condra J.H., Schleif W.A., Blahy O.M., Gabryelski L.J., Graham D.J., Quintero J.C., Rhodes A., Robbins H.L., Roth E., Shivaprakash M., Titus D., Yang T., Tepplert H., Squires K.E., Deutsch P.J., and Emini E.A. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374 (1995) 569-571
9. Datta K., Sundberg C., Karumanchi S.A., and Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res. 61 (2001) 1768-1775
10. Davis D.A., Dorsey K., Wingfield P.T., Stahl S.J., Kaufman J., Fales H.M., and Levine R.L. Regulation of HIV-1 protease activity through cysteine modification. Biochemistry 35 (1996) 2482-2488
11. Davis D.A., Newcomb F.M., Starke D.W., Ott D.E., Mieyal J.M., and Yarchoan R. Thioltransferase (glutaredoxin) is detected within HIV-1 and can regulate the activity of glutathionylated HIV-1 protease in vitro. J. Biol. Chem. 272 (1997) 25935-25940
12. Davis D.A., Yusa K., Gillim L.A., Newcomb F.M., Mitsuya H., and Yarchoan R. Conserved cysteines of the human immunodeficiency type 1 protease are involved in regulation of polyprotein processing and viral maturation of immature virions. J. Virol. 13 (1999) 1156-1164
13. Davis D.A., Newcomb F.M., Moskovitz J., Wingfield P.T., Stahl S.J., Kaufman J., Fales H.M., Levine R.L., and Yarchoan R. HIV-2 protease is inactivated after oxidation at the dimer interface and activity can be partly restored with methionine sulphoxide reductase. Biochem. J. 346 (2000) 305-311
14. Davis D.A., Brown C.A., Newcomb F.M., Boja E.S., Fales H.M., Kaufman J., Stahl S.J., Wingfield P., and Yarchoan R. Reversible oxidative modification as a mechanism for regulating retroviral protease dimerization and activation. J. Virol. 77 (2003) 3319-3325
15. Deeks S.G., and Volberding P.A. HIV-1 protease inhibitors. AIDS Clin. Rev. (1997) 145-185
16. Dumond J., Boggetto N., Schramm H.J., Schramm W., Takahashi M., and Reboud-Ravaux M. Thyroxine-derivatives of lipopeptides: bifunctional dimerization inhibitors of human immunodeficiency virus-1 protease. Biochem. Pharmacol. 65 (2003) 1097-1102
17. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., and Barsoum J. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 664-668
18. Flexner C. HIV-protease inhibitors. N. Engl. J. Med. 338 (1998) 1281-1292
19. Futaki S., Suzuki T., Ohashi W., Yagami T., Tanaka S., Ueda K., and Sugiura Y. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 (2001) 5836-5840
20. Futaki S., Goto S., Suzuki T., Nakase I., and Sugiura Y. Structural variety of membrane permeable peptides. Curr. Protein Pept. Sci. 4 (2003) 87-96
21. Gatanaga H., Suzuki Y., Tsang H., Yoshimura K., Kavlick M.F., Nagashima K., Gorelick R.J., Mardy S., Tang C., Summers M.F., and Mitsuya H. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J. Biol. Chem. 277 (2002) 5952-5961
22. Hill M., Tachedjian G., and Mak J. The packaging and maturation of the HIV-1 Pol proteins. Curr. HIV Res. 3 (2005) 73-85
23. Ishima R., Torchia D.A., Lynch S.M., Gronenborn A.M., and Louis J.M. Solution structure of the mature HIV-1 protease monomer: insight into the tertiary fold and stability of a precursor. J. Biol. Chem. 278 (2003) 43311-43319
24. Jin L.H., Bahn J.H., Eum W.S., Kwon H.Y., Jang S.H., Han K.H., Kang T.C., Won M.H., Kang J.H., Cho S.W., Park J., and Choi S.Y. Transduction of human catalase mediated by an HIV-1 TAT protein basic domain and arginine-rich peptides into mammalian cells. Free Radic. Biol. Med. 31 (2001) 1509-1519
25. Kaplan A.H., Zack J.A., Knigge M., Paul D.A., Kempf D.J., Norbeck D.W., and Swanstrom R. Partial inhibition of the human immunodficiency virus type 1 protease results in aberrant virus assembly and the formation of non-infectious particles. J. Virol. 67 (1993) 4050-4055
26. Kaplan A.H., Manchester M., and Swanstrom R. The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J. Virol. 68 (1994) 6782-6786
27. Karacostas V., Wolffe E.J., Nagashima K., Gonda M.A., and Moss B. Overexpression of the HIV-1 gag-pol polyprotein results in intracellular activation of HIV-1 protease and inhibition of assembly and budding of virus-like particles. Virology 193 (1993) 661-671
28. Krausslich H.-G. Human immunodeficiency virus proteinase dimer as component of the viral polyprotein prevents particle assembly and viral infectivity. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 3213-3217
29. In: Kuiken C.L., Foley B., Hahn B., Korber B., McCutchan F., Marx P.A., Mellors J.W.I.M.J., Sodroski J., and Wolinsky S. (Eds). HIV Sequence Compendium 2004 (2004), Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM
30. Kuzmic P., Ng K.Y., and Heath T.D. Mixtures of tight-binding enzyme inhibitors. Kinetic analysis by a recursive rate equation. Anal. Biochem. 200 (1992) 68-73
31. Lundberg M., Wikstrom S., and Johansson M. Cell surface adherence and endocytosis of protein transduction domains. Mol. Ther. 8 (2003) 143-150
32. Misson J., Clark W., and Kendall M.J. Therapeutic advances: protease inhibitors for the treatment of HIV-1 infection. J. Clin. Pharm. Ther. 22 (1997) 109-117
33. Muzammil S., Ross P., and Freire E. A major role for a set of non-active site mutations in the development of HIV-1 protease drug resistance. Biochemistry 42 (2003) 631-638
34. Oxford J.S., Coates A.R.M., Sia D.Y., Brown K., and Asad S. Potential target sites for antiviral inhibitors of human immunodeficiency virus (HIV). J. Antimicrob. Chemother. 23 Suppl. A (1989) 9-27
35. Park J., Ryu J., Jin L.H., Bahn J.H., Kim J.A., Yoon C.S., Kim D.W., Han K.H., Eum W.S., Kwon H.Y., Kang T.C., Won M.H., Kang J.H., Cho S.W., and Choi S.Y. 9-Polylysine protein transduction domain: enhanced penetration efficiency of superoxide dismutase into mammalian cells and skin. Mol. Cells 13 (2002) 202-208
36. Pettit S.C., Everitt L.E., Choudhury S., Dunn B.M., and Kaplan A.H. Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism. J. Virol. 78 (2004) 8477-8485
37. Richard J.P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M.J., Chernomordik L.V., and Lebleu B. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003) 585-590
38. Ridky T., and Leis J. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270 (1995) 29621-29623
39. Romano L., Venturi G., Giomi S., Pippi L., Valensin P.E., and Zazzi M. Development and significance of resistance to protease inhibitors in HIV-1-infected adults under triple-drug therapy in clinical practice. J. Med. Virol. 66 (2002) 143-150
40. Schmit J.C., Ruiz L., Clotet B., Raventos A., Tor J., Leonard J., Desmyter J., De Clercq E., and Vandamme A.M. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10 (1996) 995-999
41. Schramm H.J., de Rosny E., Reboud-Ravaux M., Buttner J., Dick A., and Schramm W. Lipopeptides as dimerization inhibitors of HIV-1 protease. Biol. Chem. 380 (1999) 593-596
42. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
43. Shafer R.W., Jung D.R., Betts B.J., Xi Y., and Gonzales M.J. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res. 28 (2000) 346-348
44. Shafer R.W., Winters M.A., Palmer S., and Merigan T.C. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Ann. Intern. Med. 128 (1998) 906-911
45. Shultz M.D., and Chmielewski J. Probing the role of interfacial residues in a dimerization inhibitor of HIV-1 protease. Bioorg. Med. Chem. Lett. 9 (1999) 2431-2436
46. Svicher V., Ceccherini-Silberstein F., Erba F., Santoro M., Gori C., Bellocchi M.C., Giannella S., Trotta M.P., Monforte A., Antinori A., and Perno C.F. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. Antimicrob. Agents Chemother. 49 (2005) 2015-2025
47. Takenobu T., Tomizawa K., Matsushita M., Li S.T., Moriwaki A., Lu Y.F., and Matsui H. Development of p53 protein transduction therapy using membrane-permeable peptides and the application to oral cancer cells. Mol. Cancer Ther. 1 (2002) 1043-1049
48. Todd M.J., Semo N., and Freire E. The structural stability of the HIV-1 protease. J. Mol. Biol. 283 (1998) 475-488
49. Tomasselli A.G., Olsen M.K., Hui J.O., Staples D.J., Sawyer T.K., Heinrikson R.L., and Tomich C.S. Substrate analogue inhibition and active site titration of purified recombinant HIV-1 protease. Biochemistry 29 (1990) 264-269
50. Ulysse L.G., and Chmielewski J. Restricting the flexibility of crosslinked, interfacial peptide inhibitors of HIV-1 protease. Bioorg. Med. Chem. Lett. 8 (1998) 3281-3286
51. Vives E., Brodin P., and Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997) 16010-16017
52. Weber I.T. Comparison of the crystal structures and intersubunit interactions of human immunodeficiency and Rous sarcoma virus proteases. J. Biol. Chem. 265 (1990) 10492-10496
53. Wheeler D.S., Dunsmore K.E., and Wong H.R. Intracellular delivery of HSP70 using HIV-1 Tat protein transduction domain. Biochem. Biophys. Res. Commun. 301 (2003) 54-59
54. Xie D., Gulnik S., Gustchina E., Yu B., Shao W., Qoronfleh W., Nathan A., and Erickson J.W. Drug resistance mutations can effect dimer stability of HIV-1 protease at neutral pH. Protein Sci. 8 (1999) 1702-1707
55. Yoshimura K., Kato R., Yusa K., Kavlick M.F., Maroun V., Nguyen A., Mimoto T., Ueno T., Shintani M., Falloon J., Masur H., Hayashi H., Erickson J., and Mitsuya H. JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 8675-8680
56. Zhang Z.Y., Poorman R.A., Maggiora L.L., Heinrikson R.L., and Kezdy F.J. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 266 (1991) 15591-15594
57. Zutshi R., and Chmielewski J. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett. 10 (2000) 1901-1903